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Abstract
Background: In patients with advanced non-small-cell lung cancer, vitamin D receptor (VDR) polymorphisms and
haplotypes are reported to be associated with survival. We hypothesized that a similar association would be observed in
patients with head and neck squamous-cell carcinoma (HNSCC).
Methods: In a post-hoc analysis of our previous prospective cohort study, VDR polymorphisms including Cdx2 G/A
(rs11568820), FokI C/T (rs10735810), BsmI A/G (rs1544410), ApaI G/T (rs7976091), and TaqI T/C (rs731236) were genotyped
by sequencing in 204 consecutive patients with HNSCC who underwent tumor resection. Progression-free survival was
compared between VDR polymorphisms using Kaplan-Meier survival curves with log-rank tests and Cox proportional hazard
models adjusting for age, gender, smoking status, primary tumor sites, postoperative stages, existence of residual tumor,
and postoperative treatment with chemotherapy or radiotherapy.
Results: During a median follow-up of 1,047 days, tumor progression and death occurred in 76 (37.3%) and 27 (13.2%)
patients, respectively. The FokI T/T genotype was associated with poor progression-free survival: median survival for T/T was
265 days compared with 1,127 days for C/C or C/T (log-rank test: P=0.0004; adjusted hazard ratio, 3.03; 95% confidence
interval, 1.62 to 5.67; P=0.001). In contrast, the other polymorphisms (Cdx2, BsmI, ApaI, TaqI) showed no significant
association with progression-free survival. The A-T-G (Cdx2-FokI-ApaI) haplotype demonstrated a significant association
with a higher progression rate (P=0.02).
Conclusion: These results suggest that VDR polymorphisms and haplotypes may be associated with prognosis in patients
with HNSCC, although the sample size is not large enough to draw definitive conclusions.
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Introduction
Many ecological studies demonstrate associations between UVB
rays and a lower risk of developing various cancers except skin
cancer, implying that UVB rays induce vitamin D synthesis, which
may suppress growth and induce differentiation/apoptosis of
cancer cells [1]. A plausible explanation for why higher circulating
levels of vitamin D are associated with a decreased risk of deadly
cancers is as follows [2]. Epithelial cells convert the primary
circulating form of vitamin D, 25-hydroxyvitamin D (25(OH)D),
to its active form, 1,25-dihydoroxyvitamin D, inside the cells,
which bind vitamin D receptors (VDR) in their cytoplasm to
regulate a variety of genes. These genes prevent malignant
transformation by keeping cellular proliferation and differentiation
within normal ranges. In turn, if a cell becomes malignant, 1,25-
dihydroxyvitamin D can induce apoptosis and prevent angiogen-
esis, thereby reducing the potential for the malignant cell to
survive. Recently, vitamin D has been proven to regulate
molecules related to the cell cycle and apoptosis in vitro [3,4], in
vivo [5,6], and in a pilot randomized double-blind, placebo-
controlled clinical trial [7].
Observational studies have suggested inverse associations
between serum levels of 25(OH)D and incidence rates of colon,
breast, ovarian, renal, pancreatic, aggressive prostate, and other
cancers [8,9]. Moreover, VDR FokI and BsmI single nucleotide
polymorphisms (SNPs) might modulate the risk of breast, skin, and
prostate cancer as well as other cancer sites [10,11]. To prove the
efficacy of vitamin D in primary cancer prevention, double-blind
randomized placebo-controlled trials are needed. Higher doses
(1,100IU) of vitamin D plus calcium were shown to significantly
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vitamin D did not decrease the incidence of colorectal cancer or
breast cancer [13,14].
Although there are many studies investigating associations
between serum 25(OH)D levels/VDR polymorphisms and risks of
developing cancer, only a few studies have examined the impact of
serum 25(OH)D levels on the prognosis of patients with cancer
[15–18]. Recently, Heist et al. demonstrated that the T allele of
VDR FokI polymorphism and the G-T-C (Cdx2-FokI-BsmI)
haplotype are associated with significantly worse survival in
patients with advanced non-small-cell lung cancer; this was a
report to show a relationship between VDR polymorphisms and
prognosis of patients with cancer [19].
We hypothesized that associations between VDR polymor-
phisms and prognosis may be observed not only in specific cancers
such as breast and lung cancer but also in other kinds of cancers.
Although a variety of VDR polymorphisms were reported to be
associated with different disease phenotypes in previous studies,
the functional effects of the VDR polymorphisms Cdx2 and FokI
have been confirmed [20]. In this study, we assessed associations
between five polymorphisms (Cdx2, FokI, BsmI, ApaI, and TaqI)
and progression-free survival in patients with head and neck
squamous cell carcinoma (HNSCC).
Methods
Patients
This was a post-hoc analysis of VDR polymorphisms in our
prospectivecohortstudyuptoFebruary2008 [21] plus anextension
up to August 2011. The study was approved by the Ethics
Committee for Biomedical Research of the Jikei Institutional
Review Board, Jikei University School of Medicine, Tokyo, Japan.
All patients provided written informed consent. Between September
2006 and August 2011, tumors and peripheral blood samples were
obtained from HNSCC patients who underwent surgery at the
DepartmentofHeadandNeckSurgery,JikeiUniversityHospital.A
total of 204 consecutive patients with HNSCC who underwent
tumor resection were included in this study. Clinical information
was obtained from clinical and surgical charts until September
2011. Based on postoperative staging, tumor node metastasis
(TNM) classification and cancer stages were determined according
to the 6th Union for International Cancer Control TNM
classification and stage groupings. Existence of residual tumor and
postoperative chemoradiotherapy was also checked to use in
multivariate analysis. Patients were periodically (every 0.5 to 2
months) examined on an outpatient basis to make sure they had not
progressed. Smoking index was defined as the number of cigarettes
smoked daily multiplied by the number of years of smoking.
Periodic examinations consisted of standard tests, including
endoscopy and computed tomography of the chest and neck.
Samples
In each case, tumor samples from the primary site and
surrounding normal tissue, but not metastatic sites, were stored at
280uC after excision. Cancer tissue was divided into 2 specimens: 1
for pathological confirmation, where the sample was composed of
more than 70% cancer cells, and the other for DNA extraction.
Peripheral blood samples were collected during the preoperative
period from the same patients to confirm whether alteration of the
sequence was due to genomic polymorphisms or somatic mutations.
Polymorphisms of the VDR gene
DNA was extracted from the fresh frozen tumor and peripheral
blood samples using QIAcube (Qiagen, Tokyo, Japan) following the
manufacturer’s protocol. DNA fragments including FokI and Cdx2
were amplified by polymerase chain reaction (PCR) using the
following primers (forward/reverse): for Fokl (rs10735810),
ctccgaaggcactgtgctcaggcct/atggaaacaccttgcttcttctccctc; sequence,
ggcctgggccctggggagat; parameters: denaturation at 98uC for 1 min,
followed by 30 cycles at 98uCf o r1 0s ,a n n e a l i n ga t6 8 uC for 4 min,
and the stopping reaction at 16uC. For Cdx2 (rs10735810),
gggaaggagggagggaggaaggaagg/agctgtagcaatgaaagcaaacc; sequence,
tagaaaacattgtagaacatc; parameters: denaturation at 95uC for 3 min,
followed by 30 cycles at 95uCf o r9 0s ,a n n e a l i n ga t5 9 uCf o r9 0s ,
then at 72uC for 2 min, and 16uC. For BsmI (rs1544410),
gctgagggccagctgggcaacctgaa/aaccagcgggaagaggtcaaggg; sequence,
gggcaacctgaagggagacgtagc; parameters: denaturation at 94uCf o r
3 min, followed by 35 cycles at 94uCf o r2 0s ,a n n e a l i n ga t6 2 uCf o r
40 s, extension at 72uC for 1 min, then final extension at 72uCf o r
6m i n , a n d 1 6 uC. For ApaI (rs7976091) and TaqI (rs731236),
agagcatggacagggagcaaggccaggcag/gcgcaggtcggctagcttctggatcatc: se-
quence, agagcatggacagggagcaaggccaggcag; parameters: denaturation
Table 1. Genotype and allele analyses of vitamin D receptor
gene polymorphisms.
SNPs
Genotype
Allele N HW p-value
*1
Cdx2 0.06
rs11568820 AA 28
(Promoter) GA 67
GG 77
A 123
G 221
FokI 0.08
rs10735810 CC 73
(Exon2) CT 112
TT 19
C 258
T 150
BsmI 2.7610
25
rs1544410 AA 12
(Intoron8) AG 27
GG 133
A5 1
G 293
ApaI 0.31
rs7975232 GG 96
(Intoron8) GT 61
TT 15
G 253
T9 1
TaqI 0.04
rs731236 TT 129
(Exon8) CT 38
CC 5
T 296
C4 8
*1: Hardy-Weinberg equilibrium was assessed by the chi-square test.
doi:10.1371/journal.pone.0029634.t001
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at 66uC for 30 s, extension at 72uC4 5s ,t h e nf i n a le x t e n s i o na t7 2 uC
for 10 min, and 16uC.
The PCR products were incubated with Rapid alkaline
phosphatase (Roche Diagnostics, Mannheim, Germany) and
Exonuclease I (New England BioLabs, Ipswich, MA) at 37uC for
30 min, then 80uC for 15 min. Using Big Dye Terminator v3.1
Cycle Sequencing kit (Applied Biosystems, Tokyo, Japan), the
aliquots were incubated under the following conditions: 96uC for
5 min; 25 cycles of 96uC for 10 s, 50uC for 5 s, 60uC for 2 min.
Treated PCR products were sequenced with the ABI PRISM 3700
Genetic Analyzer (Applied Biosystems, Foster City, CA). Sequenc-
ing was confirmed with independent duplicate analyses.
Statistical analysis
Mann-Whitney test and chi-square test were used to evaluate
differences in patients’ characteristics stratified by VDR genotypes.
Progression-free survival was defined as the length of living time
after surgery during which no apparent progression of cancer was
found; curves were drawn using the Kaplan-Meier method and
compared by VDR polymorphisms using log-rank tests. Cox
proportional hazard models were fitted for multivariate analysis
adjusting for age, gender, smoking status, primary tumor sites,
postoperative stage (stage I to stage IV), existence of residual
tumor, and postoperative treatment with chemotherapy or
radiotherapy. Adjusted hazard ratios (HR) and 95% confidence
intervals (CI) were computed. All statistical analyses were
performed using STATA 12.0 (STATA Corp., College Station,
TX). P,0.05 was considered statistically significant.
Hardy-Weinberg equilibrium was assessed by the chi-square
test. Linkage disequilibrium relationships of VDR SNPs that were
not significant as assessed with Hardy-Weinberg equilibrium were
visualized based on calculating D9. Genotype and allele frequen-
cies were compared between progressed and non-progressed
patients by means of chi-square analysis. Global differences in
haplotype frequencies between progressed and non-progressed
patients were assessed using 10,000 permutations for each
comparison to correct for inaccurate p-values due to multiple
comparisons. All analyses were done using Haploview [22].
Figure 1. Linkage disequilibrium plot across vitamin D receptor
gene in 172 patients with HNSCC. Numbers within the diamonds
are D9 values for the respective SNP pairs.
doi:10.1371/journal.pone.0029634.g001
Table 2. Patients’ characteristics stratified by FokI genotype.
Variable Total (n=204) Fok I C/C C/T (n=185) Fok I TT (n=19) P value
Age (years) 63.7611.2 63.4611.5 65.968.3 0.45
*1
Male/female 157/47 142/43 15/4 0.83
*2
Smoking status (pack-year) 20.9625.7 19.7624.4 32.4634.6 0.12
*1
Primary site 0.58
*2
Oropharyngeal 54 47 7
Hypopharyngeal 49 45 4
Laryngeal 36 34 2
Oral cavity 46 43 3
Nasal cavity 19 16 3
T stage: T1/T2/T3/T4 22/89/43/50 21/78/39/47 1/11/4/3 0.53
*2
N stage: N0/N1/N2 97/33/74 90/29/66 7/4/8 0.60
*2
Stage: I/II/III/IV 14/40/47/103 14/37/42/92 0/3/5/11 0.59
*2
Existence of residual tumor 10 (4.8%) 9 (4.9%) 1 (5.3%) 0.94
*2
Chemo-radio therapy 30 (14.7%) 28 (15.1%) 2 (10.5%) 0.59
*2
*1: P-value was calculated by Mann Whitney test.
*2: P-value was calculated by chi-square test.
doi:10.1371/journal.pone.0029634.t002
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Patients’ characteristics and VDR polymorphisms
Patients’ age ranged from 32 to 89 years, and there were more
men than women. More than half of patients (55%) were smokers;
64% of smokers were men. Most patients had oropharyngeal
cancer, and 51% had stage IV disease. In 10 patients, tumor tissue
was not resected completely. Thirty patients underwent chemo-
therapy or radiotherapy after surgery.
We confirmed that polymorphisms were common between the
tumor and peripheral blood samples obtained from the same
patients. Genotype and allele frequencies of the VDR polymor-
phisms are shown in Table 1. Hardy-Weinberg equilibrium test
was significant for BsmI (P=2.7610
25) and TaqI (P=0.04).
Linkage disequilibrium analysis between VDR polymorphisms was
shown (Fig. 1). D9 between ApaI and TaqI was 78. Patients’
characteristics stratified by FokI genotype are shown in Table 2.
No significant differences were observed between patients’
characteristics and FokI or other polymorphisms (data not shown).
VDR polymorphisms and progression-free survival
All 204 patients were followed for a median of 1,047 days
(range, 23 to 1224 days), during which 76 (37.3%) progressed and
27 (13.2%) died of HNSCC. Kaplan-Meier survival curves showed
that the FokI T/T genotype was associated with poor prognosis:
median progression-free survival for T/T was 265 days compared
with 1,127 days for C/C or C/T (log-rank test: P=0.0004) (Fig. 2).
In contrast, the other polymorphisms (Cdx2, BsmI, ApaI, and
TaqI) showed no significant associations with progression-free
survival (data not shown).
Cox proportional hazard models with multivariate
adjustment
Cox proportional hazard models were computed to determine
the significance of FokI with adjustment for age, gender, smoking
status, primary tumor site, postoperative stage, existence of
residual tumor, and postoperative treatment with chemotherapy
or radiotherapy (Table 3). Without multivariate analysis, the FokI
T/T genotype and stages showed a significant crude HR. With
multivariate analysis, patients with the FokI T/T genotype showed
poor prognostic markers: adjusted HR, 3.03; 95% CI, 1.62 to
5.67; P=0.001. In contrast, the other polymorphisms (Cdx2,
BsmI, ApaI, TaqI) showed no significant association with
progression-free survival (data not shown).
VDR haplotype (Cdx2-FokI- ApaI) and permutation
analyses
Because Hardy-Weinberg equilibrium test was significant for
BsmI and TaqI, only Cdx2, FokI, and ApaI were used in
haplotype analyses. Associations between VDR haplotypes and
disease progression were analyzed with permutation analysis
Figure 2. Kaplan-Meier curves of progression-free survival by
FokI polymorphism in 204 patients with HNSCC. Difference in
time until progression was compared between FokI C/C plus C/T and T/
T.
doi:10.1371/journal.pone.0029634.g002
Table 3. Cox proportional hazard models.
Variable Crude HR 95% CI P value Adjusted HR* 95% CI P value
FokI T/T 2.73 1.52–4.89 0.001 3.03 1.62–5.67 0.001
FokI C/C+C/T Reference Reference
Age 0.99 0.97–1.01 0.48 0.98 0.96–1.01 0.14
Male 1.22 0.69–2.14 0.50 1.38 0.75–2.56 0.30
Smoking index 1.00 0.99–1.01 0.58 1.00 0.99–1.01 0.48
Primary site
Oropharyngeal Reference Reference
Hypopharyngeal 0.98 0.51–1.89 0.96 1.00 0.51–1.97 0.99
Laryngeal 0.98 0.48–2.02 0.96 1.14 0.54–2.42 0.77
Oral cavity 0.98 0.52–1.88 0.96 1.14 0.59–2.24 0.69
Nasal cavity 1.66 0.75–3.68 0.21 1.60 0.71–3.62 0.26
Stages I,IV 1.54 1.18–2.01 0.002 1.60 1.20–2.15 0.002
Existence of residual tumor 1.18 0.43–3.22 0.75 1.36 0.47–3.91 0.57
Chemoradiotherapy 1.18 0.64–2.19 0.60 1.40 0.73–2.70 0.32
*Adjusted for age, gender, smoking status, primary tumor sites, postoperative stages, existence of residual tumor, and postoperative treatment with chemotherapy or
radiotherapy.
HR, hazard ratio; CI, confidence interval.
doi:10.1371/journal.pone.0029634.t003
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a significant association with a higher progression rate (P=0.02).
Discussion
In this study, we found that the VDR FokI T/T genotype was
associated with a poor progression-free survival rate in patients
with HNSCC, even after adjusting for age, gender, smoking status,
primary tumor site, cancer stage, residual tumor, and postoper-
ative treatment (chemotherapy or radiotherapy). Arai et al.
demonstrated that compared with the FokI T/T genotype, FokI
C/C had 1.7-fold greater function of vitamin D-dependent
transcriptional activation of a reporter construct under the control
of a vitamin D response element in transfected HeLa cells [23]. By
switching from the ATG (FokI T) to the ACG (FokI C)
polymorphism, the first potential start site moved to the 39
direction, resulting in proteins that were 3 amino acids shorter and
more functional [24,25]. Thus, patients with FokI T/T may have
less response to vitamin D, resulting in a higher progression rate.
The haplotype A-T-G (Cdx2-FokI-ApaI) was associated with
poor prognosis. This result is similar to previous studies showing
that lower serum 25(OH)D levels and the Fokl T/T genotype as
well as a VDR haplotype (Cdx2-FokI-BsmI) were associated with
poor prognoses in colorectal cancer and lung cancer, respectively
[15,19].
There are many reports suggesting that vitamin D can reduce
tumor growth of HNSCC in vitro and in vivo. Activated vitamin D3
analogue EB1089 at nanomolar concentrations completely
inhibited growth of HNSCC cells [26]. Using KB cells from an
oral floor with squamous cell carcinoma, vitamin D3 was shown to
suppress cell proliferation, induce apoptosis and cell cycle arrest,
upregulate sensitivity of chemotherapeutic drugs, and downregu-
late several angiogenesis factors and an apoptotic factor, survivin
[27]. Similarly, vitamin D3 analogue inhibited the proliferation of
human laryngeal squamous carcinoma cells through the cyclin-
dependent kinase inhibitor p57 or p21 [28,29]. Moreover,
systemic vitamin D3 therapy delayed carcinogenesis in the
hamster buccal pouch model [30]. Treatment of HNSCC patients
with activated vitamin D reduced levels of immune inhibitory
CD34 (+) cells while increasing maturation of dendritic cells [31],
where a reduced progression rate can be expected [32]. FokI and
TaqI polymorphisms in VDR were reported to affect the
development of HNSCC [33]. These findings are not inconsistent
with our results.
There are several limitations to our study. Overall, the sample
size is not large enough to detect significant differences of minor
VDR polymorphisms or synergistic effects of the gene-environ-
ment and stratification by tumor stage or primary site. Although
FokI TT was a significant factor, the number was only 17 and
95%CI was sometimes wide. However, when we set number of
patients as 175 FokI CC+CT vs. 19 FokI TT polymorphisms,
post-hoc power calculations showed 98% along with a hazard
ratio of 2.73. Moreover, we did not use restriction fragment length
polymorphism analysis and directly sequenced PCR fragments to
avoid misclassification as much as possible and to compensate for
the disadvantage of the small sample size. No information was
available regarding vitamin D intake (dietary or supplemental), sun
exposure, or circulating vitamin D levels of patients. Moreover, we
did not have clinical information on alcohol use, human papilloma
virus, or Epstein-Barr virus infection. There are other kinds of
VDR polymorphisms related to disease risks that have been
reported in previous articles, and we need to expand our range of
analysis in the future.
In conclusion, there were significant associations between
shorter progression-free survival time in patients with HNSCC
and FokI T/T genotype as well as A-T-G (Cdx2-FokI-ApaI)
haplotype, although the sample size is not large enough to detect
significant differences of minor VDR polymorphisms or synergistic
effects of the gene-environment and stratification by tumor stage
or primary site.
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